Trial of Mifepristone in Combat Veterans With Posttraumatic Stress Disorder
Status:
Unknown status
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The investigators propose to conduct a randomized double-blind, parallel-group,
placebo-controlled trial of mifepristone in veterans with military-related posttraumatic
stress disorder (PTSD). This study will examine the clinical, neuropsychological, and
neuroendocrine effects of short-term treatment of mifepristone (600 mg/day for one week) to
determine if this treatment is efficacious in improving PTSD symptoms, cognitive functioning,
or other related clinical measures. Additionally, the investigators will observe whether
baseline neuroendocrine activity, or other clinical or neuropsychological factors predict the
response to mifepristone, and whether mifepristone-induced changes in neuroendocrine activity
are associated with treatment outcome.